The study was aimed to evaluate the efficacy and the tolerability of Felbamate (FLB) in adult patients with refractory partial epilepsy. Felbamate was given as add-on therapy, according to a multicenter; randomized, double- blind, placebo-controlled trial. Felbamate resulted significantly more effective than Placebo in reducing the percentage of seizures; in 38% of patients treated with FLB a reduction of seizures greater than 50% was obtained and 11% of them resulted seizure-free. Adverse experiences with FLB were considered generally mild or moderate.
|Translated title of the contribution||Felbamate as add-on therapy in adult patients with partial drug- resistant epilepsy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Clinical Neurology